Thrombopoietin Does Not Induce Lineage-restricted Commitment of Mpl-R Expressing Pluripotent Progenitors but Permits Their Complete Erythroid and Megakaryocytic Differentiation
Overview
Affiliations
In this study, we examined the in vitro and in vivo effects of forced expression of Mpl-R (the thrombopoietin receptor) on the progeny of murine hematopoietic stem cells. Bone marrow cells from 5-FU-treated mice were transduced with retroviral vectors containing the human Mpl-R cDNA, or the neomycine gene as a control. After 7 days cocultivation on virus-producer cells, GpE86-Mpl-R or Gp86-Neo, the types of hematopoietic progenitor cells responding to thrombopoietin (TPO) were studied by clonogenic assays. Mpl-R-infected cells gave rise to CFU-GEMM, BFU-E, CFU-MK, but not CFU-GM while Neo-infected cells produced only megakaryocytic colonies. In addition, when nonadherent cells from GpE86-Mpl-R cocultures were grown with TPO as the only stimulus for 7 days, a marked expansion of CFU-GEMM, BFU-E, and CFU-MK was observed, while no change in CFU-GM number was seen. Erythroid and megakaryocytic maturation occurred in the presence of TPO while a block in granulocytic differentiation was observed at the myeloblast stage. The direct effects of TPO on Mpl-R-transduced progenitor cells were demonstrated by single cell cloning experiments. To analyze the effects of the constitutive expression of Mpl-R on the determination of multipotent progenitors (CFU-S) and long-term repopulating stem cells, Mpl-R- or Neo-infected cells were injected into lethally irradiated recipient mice. No difference was seen in (1) the number of committed progenitor cells contained in individual CFU-S12 whether colonies arose from noninfected or Mpl-R-infected CFU-S; (2) the mean numbers of progenitor cells per leg or spleen of mice reconstituted with Mpl-R- or Neo-infected cells, 1 or 7 months after the graft; and (3) the blood parameters of the two groups of animals, with the exception of a 50% reduction in circulating platelet counts after 7 months in mice repopulated with Mpl-R-infected bone marrow cells. These results indicate that retrovirus-mediated expression of Mpl-R in murine stem cells does not modify their ability to reconstitute all myeloid lineages of differentiation and does not result in a preferential commitment toward the megakaryocytic lineage.
The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN.
Spivak J, Moliterno A Front Oncol. 2021; 11:641613.
PMID: 33777803 PMC: 7987816. DOI: 10.3389/fonc.2021.641613.
Spivak J, Merchant A, Williams D, Rogers O, Zhao W, Duffield A PLoS One. 2020; 15(6):e0232801.
PMID: 32479500 PMC: 7263591. DOI: 10.1371/journal.pone.0232801.
Gene therapy of MPL deficiency: challenging balance between leukemia and pancytopenia.
Wicke D, Meyer J, Buesche G, Heckl D, Kreipe H, Li Z Mol Ther. 2009; 18(2):343-52.
PMID: 19844195 PMC: 2839299. DOI: 10.1038/mt.2009.233.
Yunis E, Romero V, Diaz-Giffero F, Zuniga J, Koka P J Stem Cells. 2008; 2(4):237-248.
PMID: 19005583 PMC: 2581831.
Lannutti B, Epp A, Roy J, Chen J, Josephson N Blood. 2008; 113(8):1778-85.
PMID: 18796624 PMC: 2647669. DOI: 10.1182/blood-2007-11-124859.